Healthcare Executive Focused on Personalized Medicine, ILLUMINA
Gautam Kollu leads worldwide market development efforts for Illumina’s Reproductive & Genetic Health business. His teams are responsible for identifying and nurturing new markets for the application of NGS in diagnostics such as non-invasive prenatal testing, pre-implantation genetic screening and diagnosis, and pre-conception and newborn screening. Gautam is accomplished in the launch and commercialization of innovative healthcare technologies, having held leadership and executive roles in driving several successful products including Herceptin, Avastin, Kadcyla, Cometriq, Panorama, verifi and VeriSeq. He currently chairs the Global Fertility Alliance and tweets from @gautamkollu. He received an MBA from The Wharton School and a B. Tech. in Chemical Engineering from IIT Bombay.
Innovative Advances in Non-Invasive Prenatal Testing
Based on next generation sequencing and the discovery of cell free fetal DNA in maternal blood, NIPT has become the fastest adopted clinical genomics test. This session will cover some of the advances since NIPT’s introduction in 2012, including the expansion of testing panels to include new genetic aberrations that were previously considered too rare or too technically demanding to test for. Also covered will be cases that describe the clinical impact of these innovations in NIPT.